Market Size of Global Rare Hemophilia Factors Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 4.30 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Rare Hemophilia Factors Market Analysis
The rare hemophilia factors market is expected to record a CAGR of 4.3% over the forecast period (2022-2027).
The COVID-19 outbreak notably impacted the healthcare sector. As per the article published in 2022 under the title 'Acquired Hemophilia A Developed Post COVID-19 Vaccine: An Extremely Rare Complication', eight days after receiving the first dose of the COVID-19 vaccine, an elderly man with a history of autoimmune illnesses (polymyalgia rheumatica) and hepatitis C virus experienced the development of Acquired Hemophilia A (AHA). Moreover, as per the article published in 2022 under the title 'The Mixed Effects of the First COVID-19 Lockdown on Patients With Hemophilia', the study results showed that the frequency of bleeding episodes remained unchanged or decreased in 81% of children and 78% of adults with hemophilia during the lockdown. Hence as per the factors mentioned above, COVID-19 had a significant impact on the rare hemophilia factors market.
Certain factors are driving the market growth including rising adoption and approval of new treatment techniques, a growing number of government initiatives, and funding. For instance as per the article published in 2021 under the title 'Recent Advances in the Treatment of Hemophilia: A Review', a new era of prevention and treatment of bleeding started with the introduction of a bi-specific monoclonal antibody that clones the effects of FVIII in the tenase complex, moreover other non-replacement therapies are also in development.
Similarly, according to the World Hemophilia Federation's annual global survey conducted in a period of 1999 to 2020, the number of people affected with hemophilia was 347,026 in 2020. Scientists have reported that hemophilia is three times more prevalent in men worldwide than previously thought and is still associated with a poorer life expectancy, especially in low-income countries. Therefore, the increase in hemophilia is associated with the increasing demand for the Rare Hemophilia Factors Market.
As per the aforementioned factors, the rare hemophilia factors market is likely to grow over the forecast period. However, the high cost associated with hemophilia treatment restrains the market growth.
Rare Hemophilia Factors Industry Segmentation
As per the scope of the report, hemophilia is a genetic bleeding disorder that prevents the blood from clotting normally. The primary symptom is uncontrolled, often spontaneous bleeding in different areas of the body. The deficiency of fibrinogen, prothrombin, factor V (FV), FVII, FVIII, FIX, FX, FXI, and FXIII, called rare coagulation disorders (RCDs), may result in coagulopathies leading to spontaneous or post trauma and post surgery hemorrhages. The Rare Hemophilia Factors Market is segmented by Treatment (Factor Concentrate, Fresh Frozen Plasma, Cryoprecipitate, Others) and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Treatment | |
| Factor Concentrate | |
| Fresh Frozen Plasma (FFP) | |
| Cryoprecipitate | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Rare Hemophilia Factors Market Size Summary
The rare hemophilia factors market is poised for growth, driven by advancements in treatment techniques and increased government support. The introduction of bi-specific monoclonal antibodies and non-replacement therapies has marked a significant shift in the prevention and treatment of bleeding disorders. Despite the challenges posed by the COVID-19 pandemic, which affected the frequency of bleeding episodes, the market has shown resilience. The prevalence of hemophilia, particularly in men and low-income countries, continues to drive demand for innovative treatments. However, the high cost of these therapies remains a significant barrier to market expansion.
Fresh frozen plasma (FFP) is expected to experience growth within the rare hemophilia factors market, fueled by ongoing research and development. The increasing use of FFP in treating coagulopathies and liver diseases highlights its importance in managing bleeding disorders. North America, with its high prevalence of hemophilia and awareness initiatives, is anticipated to be a key region for market growth. The competitive landscape features major players like Baxter Healthcare, Bayer Healthcare, and Takeda Pharmaceutical Co. Ltd., who are actively expanding their portfolios and receiving regulatory approvals for new therapies. These developments underscore the dynamic nature of the market and its potential for continued expansion.
Global Rare Hemophilia Factors Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Adoption and Approval of New Treatment Techniques
-
1.2.2 Growing Number of Government Initiatives and Funding
-
-
1.3 Market Restraints
-
1.3.1 High Cost of Treatment
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
2.1 By Treatment
-
2.1.1 Factor Concentrate
-
2.1.2 Fresh Frozen Plasma (FFP)
-
2.1.3 Cryoprecipitate
-
2.1.4 Others
-
-
2.2 Geography
-
2.2.1 North America
-
2.2.1.1 United States
-
2.2.1.2 Canada
-
2.2.1.3 Mexico
-
-
2.2.2 Europe
-
2.2.2.1 Germany
-
2.2.2.2 United Kingdom
-
2.2.2.3 France
-
2.2.2.4 Italy
-
2.2.2.5 Spain
-
2.2.2.6 Rest of Europe
-
-
2.2.3 Asia Pacific
-
2.2.3.1 China
-
2.2.3.2 Japan
-
2.2.3.3 India
-
2.2.3.4 Australia
-
2.2.3.5 South Korea
-
2.2.3.6 Rest of Asia-Pacific
-
-
2.2.4 Middle East and Africa
-
2.2.4.1 GCC
-
2.2.4.2 South Africa
-
2.2.4.3 Rest of Middle East and Africa
-
-
2.2.5 South America
-
2.2.5.1 Brazil
-
2.2.5.2 Argentina
-
2.2.5.3 Rest of South America
-
-
-
Global Rare Hemophilia Factors Market Size FAQs
What is the current Global Rare Hemophilia Factors Market size?
The Global Rare Hemophilia Factors Market is projected to register a CAGR of 4.30% during the forecast period (2024-2029)
Who are the key players in Global Rare Hemophilia Factors Market?
Bayer AG, Pfizer, Inc., Takeda Pharmaceutical Co. Ltd., Sanofi S.A and Novo Nordisk are the major companies operating in the Global Rare Hemophilia Factors Market.
